| Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic EML4-ALK by disruption of an atypical β-propeller domain MW Richards, EWP Law, LVP Rennalls, S Busacca, L O’Regan, AM Fry, ... Proceedings of the National Academy of Sciences 111 (14), 5195-5200, 2014 | 105 | 2014 |
| The oncogenic transcription factor RUNX1/ETO corrupts cell cycle regulation to drive leukemic transformation N Martinez-Soria, L McKenzie, J Draper, A Ptasinska, H Issa, S Potluri, ... Cancer Cell 34 (4), 626-642. e8, 2018 | 97 | 2018 |
| A systematic survey of expression and function of zebrafish frizzled genes M Nikaido, EWP Law, RN Kelsh PloS one 8 (1), e54833, 2013 | 46 | 2013 |
| Resistance to HSP90 inhibition involving loss of MCL1 addiction S Busacca, EWP Law, IR Powley, DA Proia, M Sequeira, J Le Quesne, ... Oncogene 35 (12), 1483-1492, 2016 | 37 | 2016 |
| Optimized induction of mitochondrial apoptosis for chemotherapy-free treatment of BCR-ABL+ acute lymphoblastic leukemia M Scherr, H Kirchhoff, K Battmer, K Wohlan, CW Lee, M Ricke-Hoch, ... Leukemia 33 (6), 1313-1323, 2019 | 22 | 2019 |
| Sox10 contributes to the balance of fate choice in dorsal root ganglion progenitors M Delfino-Machin, R Madelaine, G Busolin, M Nikaido, S Colanesi, ... PLoS One 12 (3), e0172947, 2017 | 21 | 2017 |
| PS914 CONDITIONAL MEF2C EXPRESSION IN THE MOUSE THYMUS DRIVES DEVELOPMENT OF T/B‐BIPHENOTYPIC LYMPHOID LEUKEMIA/LYMPHOMA K Canté‐Barrett, Y van Helsdingen, S Goossens, E Vroegindeweij, ... HemaSphere 3, 412, 2019 | 1 | 2019 |
| Novel mechanisms of sensitivity and acquired resistance to Hsp90 inhibition by Ganetespib S Busacca, H Pringle, E Law, L O'Regan, A Fry, KB Matchett, V Reichert, ... World Conference on Lung Cancer, 2013 | 1 | 2013 |
| P309: IMAGE-BASED HIGH-CONTENT DRUG SENSITIVITY SCREENING IDENTIFIES CONVENTIONAL, EMERGING, AND POTENTIAL NOVEL THERAPEUTIC TARGETS IN HIGH-RISK ADULT ACUTE LYMPHOBLASTIC LEUKEMIA H Bell, M Singh, H Blair, A Poll, E Law, O Heidenreich, F van Delft, ... HemaSphere 6, 210-211, 2022 | | 2022 |
| Ex vivo and in vivo complex drug combination analysis for improved efficacy and specificity in high-risk childhood acute lymphoblastic leukaemia E Law, L McKenzie, H Blair, K Szoltysek, M Singh, S Bomken, J Lunec, ... Klinische Pädiatrie 234 (03), 0063, 2022 | | 2022 |
| Whole-genome CRISPR screen as a tool to identify mechanism of relapse and potential targets for novel drug combinations K Szoltysek, H Blair, R Tirtakusuma, S Nakjang, E Law, L McKenzie, ... Klinische Pädiatrie 232 (03), 2020 | | 2020 |
| High-throughput imaging analysis for drug combination efficacy in childhood acute lymphoblastic leukaemia EW Law, L McKenzie, H Blair, D Bulmer, D Pal, K Szoltysek, J Lunec, ... Klinische Pädiatrie 232 (03), 2020 | | 2020 |
| Whole-Genome CRISPR Screen Reveals the Mechanism of Relapse in Patient-Derived Cells Representing High-Risk Paediatric ALL K Szoltysek, H Blair, S Nakjang, R Tirtakusuma, M Singh, R Nelson, ... Blood 134, 3952, 2019 | | 2019 |
| Genome-wide CRISPR screen in patient derived cells reveals the mechanism of ALL chemoresistance K Szoltysek, K Dormon, H Blair, R Tirtakusuma, C Dodd, E Law, ... Klinische Pädiatrie 231 (03), 45, 2019 | | 2019 |
| Optimized Induction of Mitochondrial Apoptosis By Combination Therapies with Venetoclax for Chemotherapy-Free Treatment of BCR-ABL+ Acute Lymphoblastic Leukemia in Preclinical … M Eder, H Kirchhoff, K Battmer, K Wohlan, M Ricke-Hoch, S Erschow, ... Blood 132, 4025, 2018 | | 2018 |
| Investigating novel drug combinations against patient-derived xenografts of acute lymphoblastic leukaemia E Law, L McKenzie, K Szoltysek, J Lunec, J Irving, J Vormoor, ... Klinische Pädiatrie 230 (03), 16, 2018 | | 2018 |
| Determining mechanisms of sensitivity and resistance to HSP90 inhibition in non-small cell lung cancer EWP Law University of Leicester, 2016 | | 2016 |
| TARGETING MCL1 AMPLIFICATION IN NSCLC THROUGH ANTHRACYCLINE-MEDIATED TRANSCRIPTIONAL SUPPRESSION S Busacca, E Law, K Gately, KJ O'Byrne, EF Smit, HJM Groen, J Harrison, ... JOURNAL OF THORACIC ONCOLOGY 8, S501-S502, 2013 | | 2013 |
